Pirfenidone 267 MG [Esbriet] ( DrugBank: Pirfenidone )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 228 | 閉塞性細気管支炎 | 1 |
228. 閉塞性細気管支炎
臨床試験数 : 97 / 薬物数 : 118 - (DrugBank : 32) / 標的遺伝子数 : 33 - 標的パスウェイ数 : 156
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03315741 (ClinicalTrials.gov) | March 1, 2018 | 5/10/2017 | The Safety and Tolerability of Pirfenidone for BOS After HCT | The Safety and Tolerability of Pirfenidone for Bronchiolitis Obliterans Syndrome After Hematopoietic Cell Transplantation | Bronchiolitis Obliterans;Graft Vs Host Disease | Drug: Pirfenidone 267 MG [Esbriet] | Stanford University | Genentech, Inc. | Completed | 18 Years | N/A | All | 30 | Phase 1 | United States |